​

Bluejay Diagnostics (BJDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BJDX Stock Forecast

Bluejay Diagnostics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

BJDX Analyst Ratings

Buy

According to 1 Wall Street analysts, Bluejay Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for BJDX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 12, 2022Dawson JamesBuyInitialise

Bluejay Diagnostics's last stock rating was published by Dawson James on Jan 12, 2022. The company Initialise its BJDX rating from "null" to "Buy".

Bluejay Diagnostics Financial Forecast

Bluejay Diagnostics Revenue Forecast

Dec 24Sep 24Jun 24Mar 23
Revenue----
Avg Forecast---$809.00K
High Forecast---$809.00K
Low Forecast---$809.00K
# Analysts---1
Surprise %----

Bluejay Diagnostics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BJDX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Bluejay Diagnostics EBITDA Forecast

Dec 24Sep 24Jun 24Mar 23
# Analysts---1
EBITDA---$-2.68M
Avg Forecast---$485.40K
High Forecast---$485.40K
Low Forecast---$485.40K
Surprise %----5.52%

undefined analysts predict BJDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bluejay Diagnostics's previous annual EBITDA (undefined) of $NaN.

Bluejay Diagnostics Net Income Forecast

Dec 24Sep 24Jun 24Mar 23
# Analysts---1
Net Income---$-2.24M
Avg Forecast$-344.01M$-344.01M$-347.88K$-4.59B
High Forecast$-344.01M$-344.01M$-347.88K$-4.59B
Low Forecast$-344.01M$-344.01M$-347.88K$-4.59B
Surprise %---0.00%

Bluejay Diagnostics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BJDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bluejay Diagnostics SG&A Forecast

Dec 24Sep 24Jun 24Mar 23
# Analysts---1
SG&A---$1.33M
Avg Forecast---$4.04M
High Forecast---$4.04M
Low Forecast---$4.04M
Surprise %---0.33%

Bluejay Diagnostics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to BJDX last annual SG&A of $1.33M (Mar 23).

Bluejay Diagnostics EPS Forecast

Dec 24Sep 24Jun 24Mar 23
# Analysts---1
EPS---$-0.11
Avg Forecast$-36.00$-36.00$-0.72$-480.00
High Forecast$-36.00$-36.00$-0.72$-480.00
Low Forecast$-36.00$-36.00$-0.72$-480.00
Surprise %---0.00%

According to undefined Wall Street analysts, Bluejay Diagnostics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BJDX previous annual EPS of $NaN (undefined).

Bluejay Diagnostics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BJDXBluejay Diagnostics$4.38$10.00128.31%Buy
HSCSHeart Test Laboratories$3.85$3.00-22.08%Buy

BJDX Forecast FAQ

Is Bluejay Diagnostics a good buy?

Yes, according to 1 Wall Street analysts, Bluejay Diagnostics (BJDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BJDX's total ratings.

What are Bluejay Diagnostics's analysts' financial forecasts?

BJDX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-688M (high $-688M, low $-688M), average SG&A $0 (high $0, low $0), and average EPS is $-72.72 (high $-72.72, low $-72.72).